Status:
TERMINATED
Recombinant Human Relaxin for the Treatment of Decompensated CHF
Lead Sponsor:
Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies
Conditions:
Congestive Heart Failure (CHF)
Eligibility:
All Genders
19+ years
Phase:
PHASE2
Brief Summary
Two doses of relaxin will be compared to placebo for the treatment of patients with decompensated CHF
Detailed Description
Pilot clinical data suggest that recombinant human relaxin may be effective in treating patients with decompensated CHF. This study will randomize patients in blinded manner to one of two doses of int...
Eligibility Criteria
Inclusion
- Hospitalization
- Decompensated chronic CHF (NYHA Class III-IV)
- LVEF \< 35%
- PCWP \> 22 mmHg
- CI \< 2.3 L/min/m2
Exclusion
- Acute CHF
- Acute coronary syndrome
- Hypotension or shock
- Recent stroke
- Allergy or sensitivity to test agents
- Significant confounding conditions or medications
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2007
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT00406575
Start Date
November 1 2006
End Date
January 1 2007
Last Update
May 7 2014
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Russian Scientific Centre of Surgery n.a. B.V.Petrovsky of Russian Academy of Medical Sciences
Moscow, Russia, 119992
2
Educational Scientific Medical Center of the General Management Department of the President of Russian Federation. City Clinical Hospital №51
Moscow, Russia, 121309